FY2024 EPS Estimates for Integer Boosted by Zacks Research

Integer Holdings Co. (NYSE:ITGR) – Equities researchers at Zacks Research increased their FY2024 EPS estimates for Integer in a note issued to investors on Tuesday, January 7th. Zacks Research analyst D. Dey now expects that the medical equipment provider will post earnings of $5.33 per share for the year, up from their prior forecast of $5.32. The consensus estimate for Integer’s current full-year earnings is $5.33 per share. Zacks Research also issued estimates for Integer’s Q1 2025 earnings at $1.32 EPS, Q4 2025 earnings at $1.67 EPS, Q2 2026 earnings at $1.55 EPS and Q4 2026 earnings at $1.76 EPS.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share for the quarter, beating analysts’ consensus estimates of $1.36 by $0.07. The firm had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. Integer had a net margin of 6.70% and a return on equity of 11.63%. Integer’s revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the company posted $1.27 earnings per share.

A number of other research analysts have also recently weighed in on ITGR. Bank of America lifted their price target on shares of Integer from $135.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, October 1st. KeyCorp lifted their price objective on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Piper Sandler reiterated an “overweight” rating and set a $140.00 price objective (up previously from $125.00) on shares of Integer in a research note on Friday, October 25th. Benchmark lifted their price objective on shares of Integer from $130.00 to $140.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $160.00 price objective on shares of Integer in a research note on Tuesday, December 3rd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $145.44.

Integer Trading Up 0.5 %

Shares of ITGR stock opened at $133.83 on Thursday. The stock has a market cap of $4.49 billion, a price-to-earnings ratio of 41.31, a price-to-earnings-growth ratio of 1.99 and a beta of 1.12. The company has a quick ratio of 2.09, a current ratio of 3.28 and a debt-to-equity ratio of 0.67. Integer has a fifty-two week low of $94.56 and a fifty-two week high of $142.76. The firm’s 50 day moving average price is $135.88 and its two-hundred day moving average price is $127.85.

Institutional Trading of Integer

A number of hedge funds and other institutional investors have recently made changes to their positions in ITGR. Driehaus Capital Management LLC increased its stake in Integer by 62.5% during the second quarter. Driehaus Capital Management LLC now owns 353,052 shares of the medical equipment provider’s stock valued at $40,880,000 after purchasing an additional 135,750 shares during the last quarter. Eagle Asset Management Inc. bought a new stake in Integer during the third quarter valued at $14,403,000. Point72 Europe London LLP bought a new stake in Integer during the second quarter valued at $6,241,000. Bamco Inc. NY increased its stake in Integer by 17.4% during the third quarter. Bamco Inc. NY now owns 254,377 shares of the medical equipment provider’s stock valued at $33,069,000 after purchasing an additional 37,700 shares during the last quarter. Finally, Earnest Partners LLC increased its stake in Integer by 3.2% during the second quarter. Earnest Partners LLC now owns 1,208,319 shares of the medical equipment provider’s stock valued at $139,911,000 after purchasing an additional 37,340 shares during the last quarter. Institutional investors own 99.29% of the company’s stock.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.